TY  -  
T1  - Cost analysis of a randomized stem cell mobilization study in multiple myeloma 
SN  -  /  
UR  - http://hdl.handle.net/10138/229285 
T3  -  
A1  - Varmavuo, Ville; Silvennoinen, Raija; Anttila, Pekka; Saily, Marjaana; Sankelo, Marja; Putkonen, Mervi; Ahonen, Jouni; Mahlamaki, Eija; Mantymaa, Pentti; Savolainen, Eeva-Riitta; Remes, Kari; Jantunen, Esa 
A2  -  
PB  -  
Y1  - 2016 
LA  - eng 
AB  - Upfront autologous stem cell transplantation (ASCT) is the standard therapy for younger multiple myeloma (MM) patients. MM patients usually undergo stem cell mobilization with cyclophosphamide (CY) followed by granulocyte colony-stimulating factor (G-CSF), or with G-CSF alone. A limited number of randomized studies are available comparing costs of different mobilization strategies. Eighty transplant-eligible patients aged up to 70 years with untreated MM were included in this prospective study. ... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - Stem cell mobilization; Autologous stem cell transplantation; Multiple myeloma; Cost analysis; Cyclophosphamide; Plerixafor; COLONY-STIMULATING FACTOR; PLUS G-CSF; LOW-DOSE CYCLOPHOSPHAMIDE; TRANSPLANTATION; PLERIXAFOR; CHEMOTHERAPY; STRATEGIES; GUIDELINES; EFFICACY; OUTCOMES; 3122 Cancers 
N1  -   
PP  -  
ER  -